FILTER
LATEST INTERVIEWS
Scott Cubbler
COO LIFE SCIENCES & HEALTHCARE, GLOBAL, DHL SUPPLY CHAIN
DHL Supply Chain explains how the company keeps pace with changes such as recent demand for more biosimilars and personalized drugs.
Matthew Painter
MANAGING DIRECTOR, ARDEA RESOURCES LIMITED
The lithium battery race: leading car manufacturers aim to produce 15% electrified vehicles by 2030.
Mark Bennett
CEO, S2 RESOURCES
WA remains an optimal state for mining investors given its regulatory framework and international reputation.
Rudi P. Fronk
CHAIRMAN AND CEO, SEABRIDGE GOLD
Seabridge advances at KSM - the largest undeveloped gold project in the world measured by reserves.
Peter De Leo
MANAGING DIRECTOR, LYCOPODIUM LIMITED
Lycopodium has strengthened its offering through a joint venture and, amongst its various projects around the world where it is currently operating, is its biggest project to date; First Quantum’s Mina de Cobre copper mine in Panama.
Eugenio Ferrari
PRESIDENT, PROEXPLO 2017
"Having deeper resolution in geophysics methodologies and improving drilling techniques, the land with potential will double."
Richard Bennet
MANAGING DIRECTOR, STRIKE DRILLING
Australian miners compete in the silent race for the discovery of a Tier 1 deposit .
Ryan Bignucolo
VICE PRESIDENT OF BUSINESS DEVELOPMENT, MARGAUX RESOURCES LIMITED
Margaux Resources continues to acquire properties around its Jersey-Emerald project in southern British Columbia.
Lara Groves
MANAGEMENT DIRECTOR, EXPEDIO
Data management solutions capable of handling Big Data and Internet-based storage are on the rise.
Jerko Zuvela
MANAGING DIRECTOR, ARGOSY MINERALS LTD
Worldwide lithium trends are impacted by the increasing race for electric vehicle development.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
